CD34 and ischemic cardiomyopathy: A phase I trial has assessed the safety and feasibility of the epicardial transplantation of skeletal myoblast in patients with ischemic cardiomyopathy (CAuSMIC).111 Vrtovec and his team employed CD34 + cells, and they studied intracoronary administration in patients who either had dilated cardiomyopathy112 or non-ischemic dilated cardiomyopathy.113 They also studied transendocardial administration in patients with ischemic cardiomyopathy.114 All of their studies revealed an increase in LVEF and the 6MWD, a decrease in N-terminal pro-BNP, and improved long-term survival.